Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals in an all-cash transaction valued at approximately $5.6 billion. Under the terms of the deal, Biogen will purchase all outstanding shares of Apellis for $41 per share. This strategic acquisition is designed to significantly expand Biogen's portfolio in the fields of immunology and rare-disease medicines. Company officials stated that integrating Apellis into its operations is expected to bolster both short-term and long-term revenue growth prospects. The announcement, made on a Tuesday, highlights Biogen's continued effort to diversify its therapeutic offerings beyond its traditional focus areas. By absorbing Apellis, Biogen aims to strengthen its competitive position in the biopharmaceutical sector, leveraging Apellis' specialized pipeline to address unmet medical needs in rare diseases. The deal reflects ongoing consolidation trends within the industry as major players seek to enhance their product pipelines through targeted mergers and acquisitions. This move underscores Biogen's commitment to driving innovation and delivering value to shareholders through strategic expansion into high-growth therapeutic areas.
Wire timeline
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals in an all-cash transaction valued at approximately $5.6 billion. Under the terms of the deal, Biogen will purchase all outstanding shares of Apellis for $41 per share. This strategic acquisition is designed to significantly expand Biogen's portfolio in the fields of immunology and rare-disease medicines. Company officials stated that integrating Apellis into its operations is expected to bolster both short-term and long-term revenue growth prospects. The announcement, made on a Tuesday, highlights Biogen's continued effort to diversify its therapeutic offerings beyond its traditional focus areas. By absorbing Apellis, Biogen aims to strengthen its competitive position in the biopharmaceutical sector, leveraging Apellis' specialized pipeline to address unmet medical needs in rare diseases. The deal reflects ongoing consolidation trends within the industry as major players seek to enhance their product pipelines through targeted mergers and acquisitions. This move underscores Biogen's commitment to driving innovation and delivering value to shareholders through strategic expansion into high-growth therapeutic areas.
Technology - WSJ.com